Aurobindo Pharma Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: AUROPHARMA BSE: 524804

₹1672.00

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #9 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Aurobindo Pharma Limited (this stock)	96,203	37.4	9.2%	54.0%	—	83	54	50

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹100,225 Cr

EV / EBITDA

25.7x

EV / Sales

9.01x

Market cap / Sales

8.65x

Earnings yield

2.67%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 3,041 Cr, up 3.7% YoY.

↑ Positive

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 737 Cr, up 31.9% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	2,800	1,008	737	₹12.7500
March 31, 2026	2,787	876	692	₹11.9200
Dec. 31, 2025	2,747	782	582	₹10.0200
Sept. 30, 2025	2,790	755	581	₹10.0100
June 30, 2025	2,848	750	559	₹9.6300
March 31, 2025	2,732	556	408	₹7.0300
Dec. 31, 2024	2,917	633	472	₹8.1300
Sept. 30, 2024	2,825	724	538	₹9.2100
June 30, 2024	2,460	446	329	₹5.6200
March 31, 2024	2,894	780	579	₹9.8800
Dec. 31, 2023	2,692	687	624	₹10.6500
Sept. 30, 2023	2,669	510	416	₹6.4800
June 30, 2023	2,391	426	336	₹5.4300

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	3,041	3,001	2,877	2,949	2,932	2,846	2,971	2,947	2,525	3,017	3,023	2,736	2,486
Operating revenue	2,800	2,787	2,747	2,790	2,848	2,732	2,917	2,825	2,460	2,894	2,692	2,669	2,391
Other income	242	214	130	160	84	114	54	123	65	123	331	67	95
Operating expenses	1,917	2,005	1,958	2,065	2,052	2,135	2,203	2,104	1,961	2,119	2,210	2,124	1,968
Operating profit	882	781	789	725	796	597	713	721	499	775	482	545	422
Operating profit margin	31.5%	28.0%	28.7%	26.0%	28.0%	21.8%	24.5%	25.5%	20.3%	26.8%	17.9%	20.4%	17.7%
Depreciation	69	72	72	71	70	94	68	68	67	65	64	66	60
Interest	47	47	48	57	60	61	66	52	51	53	61	37	32
Exceptional items, gain / (loss)	—	—	-17	—	—	—	—	—	—	—	—	—	—
Profit before tax	1,008	876	782	755	750	556	633	724	446	780	687	510	426
Tax	271	184	200	174	191	147	161	186	117	201	63	130	108
Net profit	737	692	582	581	559	408	472	538	329	579	624	—	—
EPS	12.75	11.92	10.02	10.01	9.63	7.03	8.13	9.21	5.62	9.88	10.65	6.48	5.43
Net profit (TTM)	2,593	2,415	2,131	2,021	1,977	1,747	1,917	2,069	—	—	—	—	—
EPS (TTM)	44.70	41.58	36.69	34.80	34.00	29.99	32.84	35.36	32.63	32.44	33.56	28.01	24.34

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	11,172	3,164	2,415
March 31, 2025	10,933	2,358	1,747
March 31, 2024	10,646	2,403	1,954
March 31, 2023	12,792	1,614	1,230

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	-3.9%	-6.4%	11,759^†	11,290^†	11,262^†	13,254^†	11,941^†	16,376^†	12,430^†	10,400^†	9,808^†
Operating revenue	-4.4%	-6.7%	11,172	10,933	10,646	12,792	11,287^†	15,769^†	12,258^†	10,303^†	9,741^†
Other income	—	—	588^†	356^†	616^†	461^†	654^†	607^†	172^†	97^†	66^†
Operating expenses	—	—	8,080^†	8,404^†	8,422^†	11,089^†	9,797^†	11,647^†	—	7,652^†	7,331^†
Operating profit	22.0%	-5.6%	3,092^†	2,529^†	2,224^†	1,703^†	1,490^†	4,122^†	—	2,651^†	2,410^†
Operating profit margin	—	—	27.7%^†	23.1%^†	20.9%^†	13.3%^†	13.2%^†	26.1%^†	—	25.7%^†	24.7%^†
Depreciation	—	—	285^†	297^†	255^†	435^†	415^†	485^†	—	355^†	286^†
Interest	—	—	213^†	230^†	183^†	115^†	17^†	29^†	131^†	53^†	45^†
Exceptional items, gain / (loss)	—	—	-17^†	0^†	0^†	0^†	-75^†	0^†	0^†	0^†	70^†
Profit before tax	25.1%	-5.6%	3,164	2,358	2,403	1,614	1,637^†	4,215^†	1,965^†	2,343^†	2,179^†
Tax	—	—	749^†	612^†	503^†	384^†	183^†	1,086^†	435^†	530^†	472^†
Net profit	25.2%	-5.1%	2,415	1,747	1,954	1,230	1,455^†	3,129^†	1,530^†	1,813^†	1,707^†
EPS	25.6%	-4.9%	41.58^†	29.99^†	32.44^†	20.99^†	24.82^†	53.41^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 19	Mar 18	Mar 17
Operating margin	27.7%^†	23.1%^†	20.9%^†	13.3%^†	13.2%^†	26.1%^†	—	25.7%^†	24.7%^†
EBIT margin	30.2%^†	23.7%^†	24.3%^†	13.5%^†	14.7%^†	26.9%^†	17.1%^†	23.3%^†	22.8%^†
PBT margin	28.3%	21.6%	22.6%	12.6%	14.5%^†	26.7%^†	16.0%^†	22.7%^†	22.4%^†
Net margin	21.6%	16.0%	18.4%	9.6%	12.9%^†	19.8%^†	12.5%^†	17.6%^†	17.5%^†
Interest coverage	15.84x^†	11.25x^†	14.16x^†	15.04x^†	97.61x^†	148.28x^†	16.01x^†	45.30x^†	49.24x^†
Dividend payout	—	—	—	—	—	—	—	—	—
Earnings retention	—	—	—	—	—	—	—	—	—
Current ratio	1.27x	1.20x	—	—	—	—	—	—	—
Quick ratio	0.90x	0.83x	—	—	—	—	—	—	—
Debt to equity	0.18x	0.23x	—	—	—	—	—	—	—
Return on equity	10.6%	8.5%	—	—	—	—	—	—	—
Return on assets	8.2%	6.3%	—	—	—	—	—	—	—
Return on capital employed	14.7%^†	12.3%^†	—	—	—	—	—	—	—
Asset turnover	0.38x	0.40x	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	2,933	-2,025	-1,072	521	2,412
March 31, 2025	1,646	-2,066	616	247	1,399
March 31, 2024	1,715	-160	-1,837	418	1,297
March 31, 2023	1,821	-3,460	1,719	354	1,467
March 31, 2022	3,727	-1,614	-2,448	614	3,113

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	29,279	22,718	22,660	4,182	0	8,022	6,299	160	2,420	2,361
March 31, 2025	27,513	20,534	20,476	4,225	400	7,689	6,420	295	2,185	2,359
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.